Market Research Report
Global Blood Testing Market - 2019-2026
|Published by||DataM Intelligence||Product code||913734|
|Published||Content info||130-180 Pages
Delivery time: 1-2 business days
|Global Blood Testing Market - 2019-2026|
|Published: October 19, 2019||Content info: 130-180 Pages||
A blood testing is an examination of various cmponents in the blood or to count different types of blood cells. Blood tests are prescribed to check disease pathogens or agents, to check for antibodies or tumor markers, or to see how well desired treatments are working. Blood tests help physician to evaluate the working conditions of organs, diagnosing diseases and risk factors for heart disease, to check if medicines are working, cases of any infection or genetic conditions and how well the blood is clotting. Blood tests take only a few minutes to complete and can be carried out in any local hospital or clinic.
The global blood testing market size was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026).
The blood testing market growth is driven by several factors such as the increased prevalence of the infectious disease, technological advancements, rise in geriatric population, rise in R&D and rising number of blood donation and blood donors.
The burden of infectious diseases are rapidly increasing worldwide. According to World Health Organization (WHO), in 2001 42% of the total reported deaths in the world were due to infectious diseases, it is estimated that by 2020 almost half of all deaths worldwide would occur due to infectious diseases. Infectious diseases occur in both developing as well as developed countries, although treatment options are much better in developed economies. Infectious diseases can be diagnosed with blood tests. With the rising prevalence of infectious diseases, the market for blood testing is also increasing for faster and easier diagnosis. Blood tests detect infections prevalent in blood as well as working of the vital body organs that might be affected by infections.
There are various technological advancements in the blood testing market. Many companies present in the segment are working for new technology advances that can detect cancer by a blood test. For instance, ApoCell, Inc., a company based in Texas, has launched ApoCell to commercialize biomarker technologies that monitor the effectiveness of cancer drugs. Through this venture, the company developed ApoStream™, a proprietary circulatory tumor cells isolation technology. Similarly, many universities, such as the University of California, San Diego are also working on cancer detection through blood tests. Many other companies are focusing on one drop diagnostics in a faster way. A San Diego based company, Genalyte can run up to 128 different tests on a single finger prick of blood in under 15 minutes. Another Silicon Valley startup, Athelas, developed a portable diagnostic device leveraging deep learning and machine vision to rapidly measure white blood cell count and to tell the medical professional whether it can identify leukemia, infections, inflammations and other diseases. The Boston and Neuchatel, a Switzerland-based company, has a diagnostic panel housed on a biochip that can deliver a test result within 15 minutes from a single drop of blood.
Geriatric population is the target population of many non-communicable chronic diseases and infectious diseases. According to the National Institutes of Health, the world's older population continues to grow at an unprecedented rate. In 2016, 8.5% of the people worldwide that is equivalent to 617 million are aged 65 or over. According to data collected by the United Nations, the elderly population worldwide is expected to reach 17% of world's population by 2050, that means will reach 1.6 billion. Blood tests are more necessary in the elderly as they require continuous monitoring for various diseases and treatment such as diabetes.
There is an increase in voluntary blood donation all over the globe. According to WHO, in 2012, around 108 million donations were collected worldwide, which is an increase over the past decade. The donated blood is screened for various infections and diseases. Few of the tests carried out are for hepatitis B and C, HIV, Syphilis, and other tests for detecting impaired antibodies. Many infectious diseases are transmitted through blood to prevent those diseases from spreading blood testing of donors is necessary. Blood testing of the donor is also done to check the compatibility of the blood group.
By product type, the global blood testing market is segmented into instruments, reagents and kits and software and services. Instruments are further segmented into outright purchase and rental purchase and reagents and kits are further segmented as NAT reagents and kits which is further classified as standards and controls, labeling and detection reagents, enzymes and polymerases, probes and primers and buffers, nucleotides and solutions and ELISA reagents & kits which is further classified as conjugates (antigen or antibody-conjugated enzyme), immunosorbents, controls, substrates and sample diluents and wash solutions and other reagents. Among these reagents and kits is expected to account for the largest market share during the forecast period (2019-2026). The kits and reagents market has the presence of a large number of local and international manufacturers, and this is because the cost involved in the manufacturing of reagents is significantly low, which further attracts the manufacturers in the segment to develop advanced products. Furthermore, reagents and kits are frequently used in various research processes, which also augments their demand.
Based on test type, the market is segmented into complete blood count, basic metabolic panel, blood enzyme tests, blood clotting tests, and blood cholesterol tests. Complete blood count is the most commonly used blood test, and it is a part of routine checkup for any person, to check the presence of disease and infections. Complete blood count can detect blood diseases and disorders such as infections, anemia, cancers, and immune system disorders. This test can measure red blood cells, white blood cells, platelets, hemoglobin, hematocrit, and mean corpuscular volume.
By technology, the global blood testing market is segmented into next-generation sequencing (NGS), nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), western blot assay, rapid tests, and others. NAT is further segmented into real-time polymerase chain reaction (PCR) and transcription-mediated amplification (TMA). ELISA is further segmented as ELISA, by platform which is further classified as fluorescence immunoassay (FIA), chemiluminescence immunoassay (CLIA) and colorimetric immunoassay (CI) and ELISA, by generation which is further classified as first-generation ELISA, second-generation ELISA, third-generation ELISA, and fourth-generation & above. Among these ELISA segment is expected to dominate the market in the period of forecast (2019-2026) due to its ability to detect and measure antibodies in the blood. This test can determine if blood has specific antibodies related to some infection. ELISA is often used as a screening tool before more in-depth tests are ordered.
Based on end user the market is segmented into hospitals, blood banks, and others. The blood bank segment is expected to hold the dominant market share over the period of forecast (2019-2026) due to the continuous increase in blood donations and rise in surgeries and accidents. A large number of organ transplantation surgeries are also helping the growth of this market.
North America is dominating the blood testing market in 2018 and estimated to hold largest market size over the forecast period (2019-2026), owing to rise in technological advancements such as cancer-detecting blood tests, miniature diagnostic devices, digital systems with faster outcomes and accurate results and favourable government initiatives such as insurance policy Medicare that fully insure all the blood tests. The U.S. has many key players operating in the region, and there is a presence of many point to care health facilities and good hospital infrastructure. The government in the U.S. offers many government waivers and sanctions such as CLIA waiver which further contributes to market growth.
Asia-Pacific is expected to grow at the highest CAGR over the period of forecast due to high population base, development in healthcare infrastructure, high unmet needs, and increase in government initiatives. According to WHO, Asia contributes to more than 50% of infectious diseases cases worldwide. Many government and non-government organizations are working towards the cause and thus making the diagnosis of theses infections fast for better treatment options. Center for Disease Control and Prevention (CDC), in collaboration with India's National Centre for Disease Control, established the India Epidemic Intelligence Service (EIS) Programme in 2012. CDC helps strengthen laboratory systems to detect and mitigate emerging infectious diseases. Based on an assessment from the National Laboratory Strengthening Initiative, CDC supported training for quality management, accreditation procedures, diagnostic tests, antimicrobial susceptibility, and biosafety and biosecurity measures.
Some of the primary key players in the market are Bio-Rad Laboratories Inc., Grifols, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomerieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson and Company and Danaher Corporation.
In the blood testing market, Bio-Rad Laboratories Inc. holds the leadership position. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, which are contributing to the growth of the blood testing market globally.
In April 2019, Bio-Rad Laboratories, Inc. announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Bio-Rad's IH-500, an automated random access system for blood typing and screening.
In April 2019, Bio-Rad Laboratories, Inc. announced that it had received U.S. Food and Drug Administration (FDA) clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.
In March 2019, Abbott announced CE Mark for its Alinity™ m diagnostics system and assays. This new technology is helpful in keeping up with the growing demand for infectious disease testing.
In January 2019, Grifols received FDA approval of Erytra Eflexis®, the latest advancement in scalable blood typing solutions.
In October 2018, Bio-Rad Laboratories, Inc. announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for IH-Reader 24, a semi-automated blood typing instrument designed for medium- to small-volume laboratories.
In October 2018, FDA approved Grifols ID CORE XT Test for molecular red blood cell typing. The efficient system analyzes 37 antigens of 10 blood group systems.
In August 2018, Grifols' Procleix® Zika Virus Assay approved by the FDA for blood screening on the Procleix® Panther® system
In January 2018, Bio-Rad Laboratories, Inc. announced that it had received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for IH-Incubator L and IH-Centrifuge L instruments to be used with the full range of Bio-Rad's IH-System Gel reagents for manual blood typing methods.
Global Blood Testing Market Methodology and Scope